EU officials have agreed to study an experimental vaccine against Lyme disease, the world’s most common tick-borne illness, its developers said Friday. Pfizer and the French-Swiss firm Valneva say trials have shown a 70 percent efficacy rate in people aged five and above for a disease that currently has no approved vaccine. Despite a disappointing […]
The post EU to study potential vaccine for Lyme disease: companies appeared first on Insider Paper.
